Cliff Asness's VKTX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 12,172 shares of Viking Therapeutics, Inc. (VKTX) worth $390,000, representing 0.00% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in VKTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 395,459 shares. Largest reduction occurred in Q1 2025, reducing 392,120 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Viking Therapeutics (VKTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Viking Therapeutics (VKTX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +12,172 | New Buy | 12,172 | $32.04 |
| Q4 2025 | -13,072 | Sold Out | 0 | $0.00 |
| Q3 2025 | -51,656 | Reduce 79.80% | 13,072 | $25.58 |
| Q2 2025 | -80,391 | Reduce 55.40% | 64,728 | $26.50 |
| Q1 2025 | -392,120 | Reduce 72.99% | 145,119 | $23.68 |
| Q4 2024 | +73,710 | Add 15.90% | 537,239 | $40.05 |
| Q3 2024 | +395,459 | Add 580.96% | 463,529 | $62.82 |
| Q2 2024 | +28,180 | Add 70.64% | 68,070 | $53.01 |
| Q1 2024 | -7,569 | Reduce 15.95% | 39,890 | $82.00 |
| Q4 2023 | -8,204 | Reduce 14.74% | 47,459 | $18.61 |
| Q3 2023 | +24,266 | Add 77.29% | 55,663 | $11.07 |
| Q2 2023 | +31,397 | New Buy | 31,397 | $16.21 |
| Q3 2022 | -122,356 | Sold Out | 0 | $0.00 |
| Q2 2022 | +78,431 | Add 178.56% | 122,356 | $2.89 |
| Q1 2022 | +43,925 | New Buy | 43,925 | $3.01 |
| Q3 2019 | -33,106 | Sold Out | 0 | $0.00 |
| Q2 2019 | +206 | Add 0.63% | 33,106 | $8.31 |
| Q1 2019 | -1,256 | Reduce 3.68% | 32,900 | $9.94 |
| Q4 2018 | -26,778 | Reduce 43.95% | 34,156 | $7.64 |
| Q3 2018 | -18,542 | Reduce 23.33% | 60,934 | $17.41 |
| Q2 2018 | +79,476 | New Buy | 79,476 | $9.49 |
Cliff Asness's Viking Therapeutics Investment FAQs
Cliff Asness first purchased Viking Therapeutics, Inc. (VKTX) in Q2 2018, acquiring 79,476 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Viking Therapeutics, Inc. (VKTX) for 21 quarters since Q2 2018.
Cliff Asness's largest addition to Viking Therapeutics, Inc. (VKTX) was in Q3 2024, adding 463,529 shares worth $29.12 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 12,172 shares of Viking Therapeutics, Inc. (VKTX), valued at approximately $390,000.
As of the Q1 2026 filing, Viking Therapeutics, Inc. (VKTX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Viking Therapeutics, Inc. (VKTX) was 537,239 shares, as reported at the end of Q4 2024.